The company’s shares fell 3.5% in volatile premarket trading on Monday as Pfizer said it would stop developing its therapy lotiglipron.
Pfizer Inc said it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice daily treatment danuglipron, as it races to rival the success of other weight loss treatments.